Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy

NCT06533826 is registered in ClinicalTrials.gov with Ana C Garrido-Castro, MD as lead sponsor.

NCT NCT06533826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy
Lead sponsor
Ana C Garrido-Castro, MD
Phase
Phase 2
Overall status
Recruiting
Start date
October 29, 2024
Completion date
August 1, 2038
Enrollment
357 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-low breast cancer, her2-negative breast cancer, metastatic breast cancer